Patent SG-11201804134Y-A (SG)
Title: Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
Inventor: PIERCE KRISTEN
IPC: G01N33/574
Filed: 2016-11-22
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau rest0) (43) International Publication Date .... .....r ,„„0 1 June 2017 (01.06.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 2017/091577 Publication Al Number (51) International Patent Classification: (74) Agents: DOHERTY, Elizabeth A. et al.; Mcneill Baur C07K 16/28 (2006.01) GO1N 33/574 (2006.01) PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US). (21) International Application Number: PCT/US2016/063332 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN BR, BW, BY, 22 November 2016 (22.11.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/258,731 23 November 2015 (23.11.2015) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/314,174 28 March 2016 (28.03.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 62/379,094 24 August 2016 (24.08.2016) US TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: FIVE PRIME THERAPEUTICS, INC. [US/US]; Two Corporate Drive, South San Francisco, (84) Designated States (unless otherwise indicated, for every California 94080 (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors: PIERCE, Kristen; Two Corporate Drive, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, South San Francisco, California 94080 (US). POWERS, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Janine; Two Corporate Drive, South San Francisco, Cali- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, fornia 94080 (US). PALENCIA, Servando; Two Corpor- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Drive, South San Francisco, California 94080 ate (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, SIKORSKI, Robert; Two Corporate Drive, South San GW, KM, ML, MR, NE, SN, TD, TG). Francisco, California 94080 (US). GHODDUSI, Majid; Published: Two Corporate Drive, South San Francisco, California 94080 (US). KRISHNAN, Kartik; Two Corporate Drive, — with international search report (Art 21(3)) South San Francisco, California 94080 (US). — with sequence listing part of description (Rule 5.2(a)) Il .4t IN IN In Il (54) Title: FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER 0 \ O TREATMENT L 3 / 4 -- (57) : Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases Oin combination with immune stimulating agents, such as inhibitors of PD-1 or PD-Ll. In some embodiments, FGFR2 inhibitors may ei comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as anti - eia ) bodies that bind to PD-1 or to PD-Ll and inhibit interactions between these proteins, as well as PD-1 fusion proteins or poly- peptides.